Clinical Trial Update: Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 dose-finding study of CP-675,206 and SU011248 in metastatic renal cell carcinoma has completed. The trial evaluated safety and identified a recommende…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• CP-675,206
• SU011248

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Renal Cell | Phase 1 | Status: COMPLETED